All In Biotech

Drug Trial Radar · NCT07450001

A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD)

A Phase Ib/II Multicenter, Randomized, Open-label, Active-controlled, Single/Multiple-dose, Dose-finding, Clinical Study of GenSci134 in Children With Growth Hormone Deficiency

Last checked: Nov 20, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

128

Planned (sponsor's estimate)

Start

Mar 6, 2026

Primary completion

Jul 18, 2028

Study completion Dec 31, 2028

Sponsor

Sponsor type
Industry
First posted
Mar 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study comprises two phases: Phase Ib and Phase II. Phase Ib is a multicenter, randomized, open-label, active-controlled, single-dose, dose-escalation to assess safety, tolerability, PK/PD profile, and immunogenicity of GenSci134 in children with GHD. Phase II is a multicenter, randomized, open-label, active-controlled, multiple-dose, parallel-group study to assess the efficacy and safety of multiple subcutaneous doses of GenSci134 at different levels versus Norditropin® in children with GHD. It will also evaluate PK/PD profile and immunogenicity to support dose selection for Phase III.

Conditions

  • Pediatric Growth Hormone Deficiency

Interventions

  • GenSci134 InjectionDrug

    only one dose of GenSci134 to be given, subcutaneous , 6 dose levels will be assigned.

  • Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®)Drug

    multiple doses of Norditropin® FlexPro® quaque die (QD) for 28 consecutive days by subcutaneous injections.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: Treatment Emergent Adverse Events (TEAEs)Time frame: From the first dose to Day 35
  2. Phase II: Annualized height velocity (AHV) at Week 24 of treatmentTime frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.